Skip to content

Inspection Record

BioLife Plasma Services L.P. — FDA 483 Findings

US FDAInspected 2026-03-20Published 2026-10-20 5 findingsMaterial and supplier controlOther quality system

Inspectors Shelley H BeausoleilThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

Failure to prevent the release of unsuitable blood and blood components for further manufacturing.

2Material and supplier control

Failure to determine the eligibility of a donor of blood or blood components before collection.

3Material and supplier control

The responsible physician improperly delegated activities related to the collection of blood and blood components.

4Other quality system

Failure to make reasonable attempts to notify a donor who has been determined not be to eligible as a donor based on eligibility criteria.

5Other quality system

The standard operating procedure fails to include written descriptions of methods for performing donor qualifying tests and measurements, including minimum and maximum values for a test or procedure whena factor in determining acceptability.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

BioLife Plasma Services L.P. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.